Loading clinical trials...
Loading clinical trials...
Anti-Amyloid Treatment in Asymptomatic Alzheimer's Disease (A4 Study)
Conditions
Interventions
Placebo
Solanezumab
Locations
68
United States
University of Alabama at Birmingham
Birmingham, Alabama, United States
Banner Health Research Institute
Phoenix, Arizona, United States
Barrow Neurological Institute
Phoenix, Arizona, United States
Banner Sun Health Research Institute
Sun City, Arizona, United States
Institute for Memory Impairment & Neurological Disorders
Irvine, California, United States
University of California - San Diego
La Jolla, California, United States
Start Date
February 28, 2014
Primary Completion Date
December 27, 2022
Completion Date
June 8, 2023
Last Updated
December 28, 2023
NCT06560255
NCT06927362
NCT07373444
NCT07310238
NCT06830824
NCT02551952
Lead Sponsor
Eli Lilly and Company
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions